Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome

Summary

The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with non-alcoholic fatty liver disease and metabolic syndrome.

Timeline

Start

2016-05-30

Primary completion

2018-10-10

Completion

2018-10-10

Outcome

Outcome not reported

Stopped (Enrollment): “Low recruitment”

Drugs

Indications